Individualized administration of colistin sulfate in patients with carbapenem-resistant Gram-negative bacilli infection based on population pharmacokinetics

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072191

Enrollment

Unknown

Registered

2023-06-06

Start date

2023-05-22

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carbapenem-resistant Gram-negative bacilli infection

Interventions

Treatment:Therapeutic Drug Monitoring

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Patients with CRO infection who are at least 18 years old and have received colistin sulfate intravenous therapy for at least 48 hours due to empirical or confirmed infection; 2) The steady-state valley concentration of colistin sulfate should be measured at least once.

Exclusion criteria

Exclusion criteria: 1) Receiving less than 4 doses of colistin sulfate intravenous therapy; 2) Patients who died within 72 hours of medication; 3) Allergic to colistin sulfate.

Design outcomes

Primary

Measure	Time frame
plasma concentration;pharmacokinetic parameters;	—

Secondary

Measure	Time frame
efficacy;nephrotoxicity;	—

Countries

China

Contacts

Public ContactLiu Taotao

The First Affiliated Hospital of Guangxi Medical University

liutaotao@gxmu.edu+86 771 535 6789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026